TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18212177
Drug: Interferon-alpha (IFN-alpha)
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha (IFN-alpha) treatment
Study: 14552410
Drug: Earnings-supplement policies
Normalized name: Polistes fuscatus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Earnings-supplement policies
Study: 1818389
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (1200, 600, 650 mg total doses)
Study: 1818389
Drug: Intramuscular artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular artemether (480 mg)
Study: 1818389
Drug: Shorter courses
Normalized name: SALICYLIC ACID 2 mg in 100 mL TOPICAL SHAMPOO [FYENACEL CALMING SHOOTER CELLANDIR HAIR LOSS-Shampoo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shorter courses of treatment
Study: 25716702
Drug: Dexamethasone (Dexsol®,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (Dexsol®, Rosemont Pharmaceuticals Ltd) 6 mg daily for 5 days, started within 24 hours of admission.
Study: 19324916
Drug: T3 (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: T3 (0.8 microg kg(‐1) bolus; 0.113 microg kg(‐1) h(‐1) infusion)
Study: 19324916
Drug: Methylprednisolone (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone (1000 mg bolus)
Study: 17531887
Drug: High-dose NaFeEDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose NaFeEDTA (56 mg/kg)
Study: 7527406
Drug: 17 beta-estradiol
Normalized name: 17 beta-estradiol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17 beta-estradiol (E2) 10 mg E2 valerate
Study: 16618907
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of surgery, radiation therapy, and chemotherapy (cisplatin and paclitaxel) along with intraoperative radiation therapy
Study: 18548234
Drug: 14-mg transdermal
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 14-mg transdermal nicotine patch
Study: 10087976
Drug: Single 4-hour
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single 4-hour infusion of 1500 mg Clodronate
Study: 10087976
Drug: Traditional 2-hour
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional 2-hour infusion of 300 mg Clodronate
Study: 8092591
Drug: Intranasal sufentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal sufentanil and midazolam (IN‐SM)
Study: 8092591
Drug: Intramuscular meperidine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular meperidine, promethazine, and chlorpromazine (IM‐MPC)
Study: 9686822
Drug: rhG‐CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhG‐CSF (10 microg/kg) administered for 3 consecutive days (0, 1, 2)
Study: 21109462
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion of 0.2 μg/kg/min (Group 2)
Study: 10677394
Drug: Intraduodenal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraduodenal administration of lactulose and rhamnose with accelerated small-bowel transit
Study: 9313390
Drug: Low intensity
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low intensity weight‐bearing exercise program (thrice‐weekly for 12 weeks)
Study: 9313390
Drug: Minimal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal treatment (education program only)
Study: 8458054
Drug: Cefadroxil (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil (30 mg/kg once daily for 10 days)
Study: 8458054
Drug: Cephalexin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cephalexin (30 mg/kg/day in two divided doses for 10 days)
Study: 22980168
Drug: Apical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical preparation size enlarged to 2 sizes larger than FABF (Group A)
Study: 22980168
Drug: Apical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical preparation size enlarged to 3 sizes larger than FABF (Group B)
Study: 22980168
Drug: Apical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical preparation size enlarged to 4 sizes larger than FABF (Group C)
Study: 22980168
Drug: Apical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apical preparation size enlarged to 6 sizes larger than FABF (Group E)
Study: 20180916
Drug: Cardiac resynchronization
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac resynchronization therapy (CRT) as initial therapy
Study: 10356736
Drug: Act-Hib vaccine
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Act-Hib vaccine
Study: 7497560
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg with sodium citrate/bicarbonate
Study: 29618012
Drug: 0.25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/kg methylphenidate
Study: 6812106
Drug: 0.50 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.50 mg/kg methylphenidate
Study: 18692788
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase support with vaginal progesterone gel (Crinone 8% gel)
Study: 25245190
Drug: Ritonavir-boosted atazanavir
Normalized name: atazanavir and ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir-boosted atazanavir (300 mg/100 mg) with 0.35 mg norethindrone
Study: 25245190
Drug: Other antiretroviral
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antiretroviral therapy known to not alter norethindrone levels
Study: 9394096
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate (TC) 100 mg/wk
Study: 9394096
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate (TC) 250 mg/wk
Study: 9394096
Drug: Testosterone cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone cypionate (TC) 500 mg/wk
Study: 3371838
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide (4 mg)
Study: 14766687
Drug: Clear ocular
Normalized name: Caladryl Clear
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clear ocular hydro-gel (Vidisic)
Study: 14766687
Drug: Ocular dexpanthenol
Normalized name: Dexpanthenol
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ocular dexpanthenol ointment (Oleovit)
Study: 12390061
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant (acenocoumarol, INR 2-3)
Study: 23709304
Drug: Oxycodone CR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone CR
Study: 21842158
Drug: Moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate dose (0.5 g/l)
Study: 21842158
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (1 g/l)
Study: 21842158
Drug: Placebo dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose (0 g/l)
Study: 19637645
Drug: Commercially available
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Commercially available phenol-based formulation
Study: 19637645
Drug: New softening
Approvals — FDA: no, EMA: no, PMDA: no
Description: New softening agent formulations
Study: 11255933
Drug: Combined pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined pharmacological and behavioral treatments
Study: 9738781
Drug: Calcipotriene ointment
Normalized name: Calcipotriene Ointment
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcipotriene ointment on weekdays and halobetasol ointment on weekends
Study: 9738781
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment on weekdays and halobetasol ointment on weekends
Study: 320478
Drug: Dextroamphetamine 10
Normalized name: dextroamphetamine 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine 10 mg with morphine
Study: 320478
Drug: Dextroamphetamine 5
Normalized name: dextroamphetamine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine 5 mg with morphine
Study: 320478
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone (3, 6 or 12 mg)
Study: 28140641
Drug: Physical rehabilitation
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical rehabilitation with sham photobiomodulation treatment
Study: 26166378
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone (5 mg)
Study: 21727006
Drug: Ibandronate 6
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 6 mg infused over 15 min and 60 min
Study: 11506105
Drug: Acupuncture (intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (intradermal needles inserted at acupoints 2.5 cm from the spinal vertebrae)
Study: 22311378
Drug: Oxazepam (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxazepam (30 mg)
Study: 2894218
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg temazepam
Study: 31433781
Drug: Placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control group receiving no active treatment.
Study: 21171525
Drug: Ringerfundin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ringerfundin infusion
Study: 9814085
Drug: Chronic dietary
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic dietary fibre supplementation (doubled from 17.5 g/day to 34.4 g/day)
Study: 23014494
Drug: Mothers supplemented
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mothers supplemented with 2 doses of 200,000 iu retinol (n = 13)
Study: 19542901
Drug: Alglucosidase alpha
Normalized name: Alglucosidase alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alglucosidase alpha 40 mg/kg biweekly
Study: 19542901
Drug: Alglucosidase alpha
Normalized name: Alglucosidase alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alglucosidase alpha treatment
Study: 2824623
Drug: 5 X
Normalized name: PAD,ABDOMINAL 5 X 9 STERILE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 X 10(4) units of human leukocyte interferon/kg of body weight for 12 doses over 14 days (total, approximately 3.6 X 10(7) units)
Study: 28512158
Drug: Subcutaneous abdominal
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous abdominal fat
Study: 9931196
Drug: Ibuprofen (1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1.2 g/day)
Study: 2688360
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of TISACID (acid‐neutralizing capacity = 78 mmol)
Study: 22020354
Drug: Casopitant 30
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant 30 mg/d
Study: 22020354
Drug: Casopitant 120
Normalized name: casopitant
DrugBank: Casopitant (DB06634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casopitant 120 mg/d
Study: 22020354
Drug: Paroxetine 30
Normalized name: PARoxetine 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 30 mg/d
Study: 19410509
Drug: Pregabalin 300mg,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin 300mg, 450mg, and 600mg daily
Study: 2839000
Drug: Rubber cup
Normalized name: Aspergillus ruber
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubber cup with standardized solution of pumice
Study: 31797680
Drug: Selective internal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective internal radiation therapy (SIRT) using 90yttrium resin microspheres
Study: 19500141
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration with isotonic saline + N-acetylcysteine (600 mg p.o. twice daily the preceding day and the day of angiography), n = 73
Study: 19500141
Drug: Intravenous hydration
Normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous hydration with isotonic saline, n = 72
Study: 16838577
Drug: Enhanced External
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced External Counterpulsation (EECP) treatment
Study: 30035670
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CG) - maintained daily physical activities (n=18)
Study: 24083350
Drug: Pantoprazole treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantoprazole treatment until esophageal mucosal healing
Study: 19185645
Drug: Anacetrapib 300
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib 300 mg once daily for 8 weeks
Study: 19185645
Drug: Anacetrapib coadministered
Normalized name: Anacetrapib
DrugBank: Anacetrapib (DB06630)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anacetrapib coadministered with atorvastatin 20 mg
Study: 14692989
Drug: Weekly visits
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly visits to supervise diet, exercise, medication education, and self-monitoring blood sugar (Group II)
Study: 14692989
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (Daily visits)
Study: 14692989
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (Weekly visits)
Study: 11720834
Drug: Dexamethasone plus
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone plus ondansetron 8 mg daily (arm B) on days 2-4
Study: 31475623
Drug: Saffron extract
Normalized name: saffron extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron extract (affron®, 14 mg b.i.d.)
Study: 25054387
Drug: Transforaminal (TF)
Normalized name: transforming growth factor beta 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transforaminal (TF) epidural injection of methylprednisolone (80 mg)
Study: 21114202
Drug: Generic Pioglitazone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Generic Pioglitazone (Utmos) 30 mg/day for 24 weeks
Study: 15795426
Drug: Carnitine supplement
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carnitine supplement
Study: 12760312
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg EGCG
Study: 12760312
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg EGCG
Study: 15580809
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg EGCG
Study: 15580809
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg EGCG
Study: 15580809
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg EGCG
Study: 12760312
Drug: 1600 mg
Normalized name: glycerin 1600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1600 mg EGCG
Study: 15230341
Drug: Cefaclor extended
Normalized name: Cefaclor Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor extended release 500‐mg tablet after high‐fat vegetarian diet
Study: 15230341
Drug: Cefaclor extended
Normalized name: Cefaclor Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor extended release 500‐mg tablet after overnight fasting
Study: 29046301
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D inadequacy (serum 25-hydroxyvitamin D concentration <50 nmol/L)
Study: 21712713
Drug: Microneedles for
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microneedles for lidocaine injection
Study: 21712713
Drug: Hypodermic needles
Normalized name: Neolus Hypodermic Needles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypodermic needles for lidocaine injection (control)
Study: 9694705
Drug: All-trans retinoic
Normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All-trans retinoic acid (RA) in combination with daunorubicin and cytarabine (DA)
Study: 31566680
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy plus endocrine therapy
Study: 17227688
Drug: High-potency zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency zoster vaccine (approximately 207,000 plaque-forming units/dose)
Study: 17227688
Drug: Low-potency zoster
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-potency zoster vaccine (approximately 58,000 plaque-forming units/dose)
Study: 17227688
Drug: High-potency zoster
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-potency zoster vaccine
Study: 17227688
Drug: Low-potency zoster
Normalized name: ZOSTER VACCINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-potency zoster vaccine
Study: 24187870
Drug: Sini injection
Normalized name: Ephedra sinica root
DrugBank: Ephedra sinica root (DB01363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sini injection (SG)
Study: 16759769
Drug: Separate DTaP
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate DTaP and IPV vaccines
Study: 18316985
Drug: Combined DTaP-IPV
Normalized name: DTaP-IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined DTaP-IPV vaccine
Study: 8981527
Drug: rHuEPO administered
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO administered subcutaneously three times weekly (group A)
Study: 8981527
Drug: rHuEPO administered
Normalized name: GlycoPEGylated™rHuEPO
DrugBank: NE-180 (DB05619)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEPO administered subcutaneously once weekly (group B)
Study: 20462570
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy (MBCT) plus treatment as usual (TAU)
Study: 2083097
Drug: Curosurf (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curosurf (200 mg/kg) via the tracheal tube
Study: 2776469
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg diflunisal twice daily
Study: 359248
Drug: 65 mg
Normalized name: opium 65 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 65 mg dextropropoxyphene plus 650 mg paracetamol 3-times daily
Study: 31613825
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) duration
Study: 22187760
Drug: Prophylactic intramuscular
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intramuscular ephedrine 0.5 mg/kg given 10 minutes before spinal anaesthesia
Study: 22187760
Drug: Prophylactic intramuscular
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic intramuscular ephedrine 0.5 mg/kg given 20 minutes before spinal anaesthesia
Study: 22187760
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Group C) received only preloading with 15 ml/kg of Ringer lactate solution
Study: 11488779
Drug: Ebastine 60
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 60 mg/day
Study: 11488779
Drug: Ebastine 100
Normalized name: ebastine
DrugBank: Ebastine (DB11742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ebastine 100 mg/day
Study: 11488779
Drug: Terfenadine 360
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine 360 mg/day
Study: 9669009
Drug: bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.5% 38 ml + 10 mg midazolam (Group M10)
Study: 9669009
Drug: bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: bupivacaine 0.5% 36 ml + 20 mg midazolam (Group M20)
Study: 2428795
Drug: MOPP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOPP chemotherapy
Study: 25380222
Drug: Individualized guided
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individualized guided internet-delivered cognitive-behavioral therapy for 8 weeks
Study: 19614942
Drug: Vildagliptin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin (100 mg)
Study: 14628981
Drug: Modafinil (100-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil (100-400 mg once daily)
Study: 9138543
Drug: Pethidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (0.3 mg x kg‐1)
Study: 29471478
Drug: Internet-delivered Cognitive-Behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered Cognitive-Behavioral Therapy for Insomnia (iCBT-I)
Study: 12610815
Drug: BAY 12‐9566
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY 12‐9566 (100 mg)
Study: 22363673
Drug: AZT monotherapy
Normalized name: AZT
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZT monotherapy
Study: 8709213
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (AZT + ddI or AZT + ddC)
Study: 7036960
Drug: Antacid (hourly)
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antacid (hourly)
Study: 18042521
Drug: Dietary plant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary plant sterols (2 g/day)
Study: 27816052
Drug: n-6 (ω6)
Normalized name: 18:3 (n-6)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-6 (ω6) meal (7.4 g; grapeseed oil)
Study: 27816052
Drug: Saturated fat
Normalized name: Saturated fat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saturated fat meal (16 g; coconut oil)